Cellectar BioSciences, Inc.
(NASDAQ : CLRB)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen Inc.
0.67%345.221.2%$624.02m
GILDGilead Sciences, Inc.
-3.53%72.920.9%$510.71m
CELGCelgene Corporation
0.24%90.371.2%$496.41m
AMGNAmgen Inc.
0.50%197.421.2%$485.34m
ILMNIllumina, Inc.
-0.34%325.883.5%$373.70m
REGNRegeneron Pharmaceuticals, Inc.
0.67%374.262.6%$315.78m
VRTXVertex Pharmaceuticals Incorporated
0.64%176.081.9%$209.08m
ALXNAlexion Pharmaceuticals, Inc.
-1.09%116.002.0%$186.59m
AAgilent Technologies, Inc.
-1.28%64.661.5%$159.27m
SRPTSarepta Therapeutics, Inc.
0.52%130.2516.6%$142.46m
NKTRNektar Therapeutics
0.13%60.035.6%$126.29m
BLUEBluebird Bio, Inc.
1.15%158.0014.6%$121.57m
EXASExact Sciences Corporation
0.33%48.8425.3%$118.82m
BMRNBioMarin Pharmaceutical Inc.
0.69%101.014.4%$118.74m
INCYIncyte Corporation
1.40%68.802.5%$111.73m

Company Profile

Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma; CLR 125, which intends to treat micrometastatic disease; CLR 124 which could detects tumors and metastases in a broad range of cancers; and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded on April 11, 2011 and is headquartered in Madison, WI.